Al Sandrock (Biogen via YouTube)
July 27, 2021 07:42 AM EDTUpdated 07:53 AM
R&D

Wav­ing off re­cent PhII flop, Bio­gen trum­pets ear­ly pos­i­tive Alzheimer's da­ta for an­ti-tau an­ti­sense

Amber Tong

Even as Bio­gen ex­ecs scram­bled to de­fend Aduhelm and paint a rosy fu­ture the drug promis­es to un­leash, R&D chief Al San­drock re­as­sured an­a­lysts …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

GSK leaves biotech trade group BIO

Am­gen and As­traZeneca share pos­i­tive re­sults in chron­ic rhi­nos­i­nusi­tis

Ei­sai slash­es Leqem­bi sales fore­cast by al­most $100M

Charles Riv­er to close ‘15 small­er sites’ as de­mand for ear­ly re­search de­clines

FDA records re­quest lands Chi­nese API man­u­fac­tur­er on blocked im­port list

sponsored

Gene ther­a­pies don’t have to cost $4 mil­lion: New pro­duc­tion plat­forms re­duce de­vel­op­ment costs and risks

A service from the Financial Times